Miguel García-Pardo, Maisam Makarem, Janice J N Li, Deirdre Kelly, Natasha B Leighl
Br J Cancer . 2022 Mar 26. doi: 10.1038/s41416-022-01776-9. Online ahead of print.
In the current era of precision medicine, the identification of genomic alterations has revolutionised the management of patients with solid tumours. Recent advances in the detection and characterisation of circulating tumour DNA (ctDNA) have enabled the integration of liquid biopsy into clinical practice for molecular profiling. ctDNA has also emerged as a promising biomarker for prognostication, monitoring disease response, detection of minimal residual disease and early diagnosis. In this Review, we discuss current and future clinical applications of ctDNA primarily in non-small cell lung cancer in addition to other solid tumours.
Read Full Article Here: https://doi.org/10.1038/s41416-022-01776-9